Stock VERA VERA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Vera Therapeutics, Inc.

Equities

VERA

US92337R1014

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
37.99 USD +2.81% Intraday chart for Vera Therapeutics, Inc. +2.37% +147.01%
May. 28 Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment MT
May. 25 Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
GL
Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)
AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
AQ
Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress
GL
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GL
Vera Therapeutics : Provides Business Update and Reports First Quarter 2024 Financial Results - Form 8-K
PU
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
GL
Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress
AQ
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
GL
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
AQ
Developing a new treatment paradigm for IgAN
AQ
Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference
GL
Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
GL
Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock
GL
Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock
GL
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
GL
Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock
AQ
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
GL
Vera Therapeutics to Host In-Person R&D Day in New York to Present Week 72 Data from Phase 2b ORIGIN Clinical Trial of Atacicept in IgAN on January 25, 2024
GL
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. VERA Stock
  4. News Vera Therapeutics, Inc.
  5. Press Releases